References
- Blondeau JM. A review of the comparative in-vitro activ-ities of 12 antimicrobial agents, with a focus on five new “res-piratory quinolones”. J Antimicrob Chemother 1999; 43 (Suppl B): 1-11.
- Bauerfeind A. Comparison of the antibacterial activity of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin clinafloxacin levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639–651.
- Aminimanizani A, Beringer P, Jellife R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoro-quinolone antibacterials. Clin Pharmacokin 2001; 40: 169–187.
- Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment. Chest 2001; 120: 2021–2034.
- Garrison J, Hooton TM. Fluoroquinolones in the treatm-net of acute uncomplicated urinary tract infections in adult women. Exp Opin Pharmacother 2001; 2: 1227–1237.
- Dudley MN. Pharmacodynamic and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991; 6A: 45S-50S.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; ninth informational supplement; M100-S9. NCCLS, Villanova, PA. 1999.
- Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101–119.
- Nagai H, Yamasaki T, Masuda M, et al. Penetration of levofloxacin into broncho-alveolar lavage fluid. Drugs 1993; 45 (suppl 3): 259.
- Bergan T, Thorsteinsson SB, Soldberg R, Bjornskau L, Kolstad IM, Johnsen S. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. Am J Med 1987; 82 (4A): 97-102.
- Gonzalez MA, Uribe F, Moisen SD, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volun-teers. Antimicrob Agents Chemother 1984; 26: 741–744.
- Letter' JT, Rogge M, Kaiser L, Echols RM, Heller AH. Pharmacokinetics of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992; 36: 993–996.
- Honeybourne D, Andrews JM, Ashby JP, Lodwick R, Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988; 43: 715–719.
- Barman Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999; 57: 363–73.
- Eli Lilly Italia. Octegra 400mg compresse moxifloxaci-na. Riassunto delle caratteristiche tecniche del prodotto [prod-uct information sheet].
- Seth SD, Beotra A, Seth S. Comparative bioavailability of two brands of norfloxacin. J Assoc Phys India 1995; 43: 324–326.
- Well M, Naber KG, Kinzig-Schippers M, Sorgel F. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single dose. Int J Antimicrob Agents 1998; 10: 31–38.
- Mathai D, Jones RN, Pfalle MA, The SENTRY Participant Group North America. Epidemiology and frequen-cy of resistance among pathogen causing urinary tract infec-tions in 1,510 hospitalized patients: a report from the SEN-TRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001; 40: 129–136.
- Garrison J, Hooton TM. Fluoroquinolones in the treat-ment of acute uncomplicated urinary tract infections in adult women. Exp Opin Pharmacother 2001; 2: 1227–1237.
- Ball P. Future of the quinolones. Sem Resp Infect 2001; 16: 215–224.
- Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentra-tion-time curve/MIC ratio as a generic predictor of fluoro-quinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627–632.
- Firsov A, Lubenko IY, Vostrov S, Kononenko OV, Zinner SH, Portnoy YA. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equief-ficient doses. J Antimicrob Chemother 2000; 46: 725–732.
- Lister P. Pharmacodynamics of moxifloxacin and lev-ofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. Clin Infect Dis 2001; 32 (Suppl 1): S33–S38.
- Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17: 331–341.
- Martin SJ, Jung R, Garvin CG. A risk-benefit assess-ment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Safety 2001; 24: 199–222.